Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 6 Risks of death and hospitalisations: subgroup analysis in patients with renal impairment

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event

Aspart vs lispro

Glulisine vs lispro

Glulisine vs aspart

Total Mortality

0.97 [0.61, 1.54]

0.56 [0.21, 1.50]

0.58 [0.24, 1.40]

CHD

1.05 [0.70, 1.60]

0.96 [0.51, 1.81]

0.91 [0.55, 1.50]

Fatal CHD

1.17 [0.79, 1.74]

1.04 [0.50, 2.16]

0.89 [0.47, 1.67]

CVD

1.12 [0.76, 1.66]

1.00 [0.56, 1.80]

0.89 [0.56, 1.41]

Fatal CVD

1.47 [0.67, 3.26]

0.68 [0.12, 3.84]

0.46 [0.10, 2.19]

Stroke

1.32 [0.50, 3.51]

0.64 [0.12, 3.34]

0.49 [0.12, 2.06]

Heart Failure

1.03 [0.65, 1.64]

0.65 [0.28, 1.52]

0.63 [0.30, 1.31]

Kidney Failure

1.20 [0.76, 1.88]

0.98 [0.47, 2.03]

0.82 [0.45, 1.48]

Hypoglycaemia

1.46 [0.45, 4.72]

1.33 [0.22, 8.20]

0.91 [0.22, 3.82]

Hyperglycaemia

3.32 [0.46, 24.19]

N/A

N/A

  1. Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. * p-value <0.05
Back to article page

Cardiovascular Diabetology – Endocrinology Reports

ISSN: 3059-4057

Contact us